Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR).

Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

The pathogens have gained an evolutionary edge as tools used against then have remained static. This is because the market for investment in new innovation has virtually dried up, thanks to a policy framework that does not provide for swift approval of new innovations or adequately reimburse companies for the investments they make to develop new drugs.

Without action, AMR threatens to undermine the very foundations of modern medicine ― killing as many as 10 million people worldwide every year by 2050 and shrinking global GDP by as much as 3.8 percent. Yet, today, Korea currently does not even have reliable data to understand AMR’s impact, much less address it.

Around the world, AMR already takes a heavy toll. According to a new Lancet report, it kills an estimated 1.27 million people globally each year. However, the response of the international community has been muted, with few incentives to invest in R&D for new antimicrobial medicines. No new class of antibiotics has been developed in 35 years, even as bacterial resistance has steadily grown and continues to strengthen each year. Older adults are more vulnerable to drug-resistant infections, and the increase in untreatable infections already being experienced among Korea’s growing number of seniors is a clear and urgent warning of a crisis that puts Koreans of all ages at great risk.

The scale of the challenge demands national strategies and international collaboration on two key battlefronts. To begin, we must continue to reduce the overuse of current antibiotics, so they remain effective for more people, for longer. This buys time for the second necessary campaign: developing new antibiotics by ensuring the market and policy incentives for the investment in new antibiotic innovation, and reimbursement policies are robust. Doing so will require novel incentives and sustained investment from governments, foundations, and the biopharmaceutical industry.

Korea trails shamefully on this pressing issue. In the 2021 AMR Preparedness Index, which tracks how countries are faring in the fight against AMR, Korea scored just 47/100 ― behind Germany, Japan, Canada, and other advanced economies. In fact, Korea scored closer to India (37) and China (37) than leaders like the United Kingdom (76) or the United States (68).

A number of policy gaps account for this lack of readiness. Korean public health campaigns are limited and smaller in scale than those in many other advanced countries. Too few Koreans understand the dimension of the AMR problem and what they can do to help. Meanwhile, provider education efforts on proper antibiotic usage are too narrow and remain inaccessible to many professionals.

Additionally, the lag between the approval of a new drug and an official reimbursement decision is 10 times longer in Korea than in Japan, reducing the availability of new medicines on the market. In fact, not one of three novel antimicrobials explored in the 2021 AMR Preparedness Index has been approved yet.

Korea needs more champions, including those working on aging and longevity issues, to address these gaps. Already, Korea’s first national action plan on AMR integrated best practices from the World Health Organization and established a robust surveillance and monitoring system to track AMR. In recent years, the Korea Disease Control and Prevention Agency and other government agencies have led efforts to reduce inappropriate usage of antibiotics for viral illnesses, track and compare usage rates between hospitals, and address overuse in livestock production.

It’s time to extend and build on these efforts. First, Korea can fully fund and support its recently released second national action plan on AMR, slated to run through 2025. A well-designed national strategy remains the foundation of a strong AMR response, and Korea must continue to support the plan’s priority areas, including antimicrobial stewardship and infection control programs in hospitals, plus R&D investments to help develop new diagnostics and drugs.

Second, policymakers and health system leaders can make AMR a public health priority. A commitment to large-scale awareness campaigns would empower both patients and providers to use antibiotics more responsibly. Making AMR training for health care professionals more accessible and more comprehensive would ensure a consistent approach across the health system. Further, Korea must invest to swell the ranks of its cadre of experts in the AMR field, including infectious disease specialists who can lead the counteroffensive against AMR.

Public officials should also design incentives for the creation and swift adoption of new antibiotics. By doing so, Korea would join AMR heroes like the U.K., which has built innovative models to pay for the public health value of new medicines. New antibiotics must be subject to careful stewardship to extend their useful life; financial success cannot depend on high unit sales. In conjunction, regulators can work to shorten the time between market approval and reimbursement approval.

If policymakers take forward-looking action to address AMR today, we can avoid desperate measures in the future. This is critical to preserving public health, economic strength, and a capable health system. It will place Korea in the global vanguard prioritizing this collective action problem with the highest possible stakes.

Dr. Kim Bong-young, Ph.D., is an associate professor of internal medicine (infectious diseases) at Hanyang University College of Medicine and director of the Isolation Ward at Hanyang University Hospital. Mike Hodin, Ph.D., is CEO of the Global Coalition on Aging.

Source: The Korea Times

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

What Old Age Might Be Like for Today’s 30-Year-Olds

Get ready for a new old age. With the U.S. fertility rate in a decadelong slump and the life expectancy of 65-year-old Americans approaching roughly 85, our aging nation is likely to grow older by midcentury, as the ratio of young to old continues to decline. The trend is likely to upend how our society is organized, making life very different for today’s 30-year-olds when they reach their 60s compared with life for 60-year-olds now.

World Population Reaches 8bn As It Grows Older

The world’s population reached 8bn people on Tuesday and will hit 9bn in 15 years as it experiences an unprecedented surge in the number of older people, according to the latest UN data. The global fertility rate has more than halved since the 1950s to 2.3 births per woman. With mortality also falling, the number of people aged 65 and over is expected to rise from 783mn in 2022 to 1bn by 2030 and reach 1.4bn by 2043, the UN population data revealed.

Global Coalition on Aging (GCOA) Launches Cross-Sector Alliance Committed to Health Innovation at High-Level Forum on The Silver Economy

Today, the Global Coalition on Aging (GCOA), along with cross-sector stakeholders representing patient advocacy, policy, industry, and academic communities, announced the launch of the Alliance for Health Innovation at the High-Level Forum on the Silver Economy in New York. The Alliance is dedicated to establishing the importance of innovation in achieving healthy aging and health equity through investments, policy reforms, and strategic partnerships.

Japan Must Face Up to Growing Danger of Drug-resistant Germs

In the wake of more than 6.4 million COVID-19 deaths worldwide and unprecedented economic destruction, the global community has no excuse to be caught unprepared for the next pandemic. Yet right now, a devastating parallel plague is already underway and worsening. Some years, it is killing well over 1 million people, according to medical journal The Lancet.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging.